P95 projects are largely focused on a broad range of infectious diseases and vaccines. However, P95 is also involved in projects related to cancer, women’s health, allergy and others, and is rapidly expanding its customer base and the scope of services.

Here is a list of some of the most requested services. Many other customised services can be provided upon request. P95 is happy to tailor services to your needs.

Accordion Content
  • Observational studies
  • Systematic literature reviews
  • Meta-analyses
  • Surveillance systems
  • Advanced statistical modelling
  • Evidence gap analysis
  • Health economics
  • Benefit-risk assessment
  • Risk management plans and pharmacovigilance strategy
  • Post-Authorisation Safety Study (PASS) protocols and studies
  • Signal detection and evaluation
  • Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC) support
  • Individual adverse event assessment
  • Aggregate reports: Periodic Safety Update Reports (PSURs), Development Safety Update Reports (DSURs)
  • Single and multi-database analyses
  • Feasibility assessments
  • Real-world data identification
  • Small cell risk analysis
  • Data visualisation
  • Data mining
Accordion Content
  • Secure data storage and sharing
  • Interactive health data dashboards
  • Algorithm development
  • Quality control and coding support
  • Scientific publications
  • Conference abstracts and presentations
  • Study reports
  • Meeting proceedings and reports
  • Various trainings in epidemiology, pharmacovigilance and statistics

Global Reach

P95 is involved in projects at a global scale. P95 is currently supporting various vaccine manufacturers in their clinical development plans as well as their post-licensure plans for COVID-19. As such, P95 has a central role in the COVIDRIVE project – a public-private partnership to estimate brand-specific COVID-19 vaccine effectiveness in Europe. P95 also had leading positions in other projects under the Innovative Medicines Initiative (IMI): ADVANCE (Accelerated development of vaccine benefit-risk collaboration in Europe), DRIVE (Development of Robust and Innovative Vaccine Effectiveness) and VITAL (Vaccines and infectious diseases in the ageing population).

Here are some examples of our most recent contributions to vaccines in development or on the market

Flu & COVID-19 vaccine impact effectiveness studies
Client: European influenza and COVID-19 vaccine manufacturers
Duration: 5 years
To monitor effectiveness of influenza and COVID-19 vaccines in Europe
Fisabio (Foundation for the Promotion of Health and Biomedical Research of Valencia Region, Spain) and THL (Finnish Institute for Health and Welfare)

Vaccine safety in pregnancy
Client: World Health Organisation
Duration: 3 years
To assess the applicability of Global Alignment of Immunisation Safety Assessment in Pregnancy (GAIA) case definitions for selected maternal and neonatal outcomes in low and middle income countries
INternational CLinical Epidemiology Network (INCLEN)

Study of the impact of COVID-19 vaccination in Brazil
Client: The Bill and Melinda Gates Foundation (BMGF)
Duration: 6 months
To measure the impact of a COVID-19 mass vaccination campaign

Escherichia coli disease epidemiology
Client: Vaccine manufacturer
Duration: >2 years
To assess the burden of disease caused by invasive E. Coli infections
Kaiser Permanente (United States not-for-profit health plan)

Lassa fever epidemiology
Client: Coalition for Epidemic Preparedness Innovations (CEPI)
Duration: 2 years
To estimate the incidence of Lassa virus infection and Lassa fever disease in five West African countries to help designing future clinical trials
CEPI, the Enable Lassa Research programme partners based in Guinea, Benin, Sierra Leone, Liberia and Nigeria, Epicentre (a not-for-profit association under Médecins sans Frontières), the Bernhard-Nocht-Institut für Tropenmedizin (BNITM), and the Margan Clinical Research Organisation (MMARCRO)

© Copyright  2021   |   P95   |   ALL RIGHTS RESERVED